CA3067857A1 - Method for reducing lung inflammation - Google Patents

Method for reducing lung inflammation Download PDF

Info

Publication number
CA3067857A1
CA3067857A1 CA3067857A CA3067857A CA3067857A1 CA 3067857 A1 CA3067857 A1 CA 3067857A1 CA 3067857 A CA3067857 A CA 3067857A CA 3067857 A CA3067857 A CA 3067857A CA 3067857 A1 CA3067857 A1 CA 3067857A1
Authority
CA
Canada
Prior art keywords
chelating agent
dose
inflammation
day
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3067857A
Other languages
English (en)
French (fr)
Inventor
Barry Clements
Original Assignee
Respirion Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902365A external-priority patent/AU2017902365A0/en
Application filed by Respirion Pharmaceuticals Pty Ltd filed Critical Respirion Pharmaceuticals Pty Ltd
Publication of CA3067857A1 publication Critical patent/CA3067857A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3067857A 2017-06-20 2018-06-20 Method for reducing lung inflammation Pending CA3067857A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902365 2017-06-20
AU2017902365A AU2017902365A0 (en) 2017-06-20 Method For Reducing Lung Inflammation
PCT/AU2018/050609 WO2018232452A1 (en) 2017-06-20 2018-06-20 METHOD FOR REDUCING PULMONARY INFLAMMATION

Publications (1)

Publication Number Publication Date
CA3067857A1 true CA3067857A1 (en) 2018-12-27

Family

ID=64735378

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3067857A Pending CA3067857A1 (en) 2017-06-20 2018-06-20 Method for reducing lung inflammation

Country Status (8)

Country Link
US (2) US11491126B2 (https=)
EP (1) EP3641749A4 (https=)
JP (3) JP7729713B2 (https=)
CN (1) CN111050762A (https=)
AU (2) AU2018286649B2 (https=)
BR (1) BR112019027257A2 (https=)
CA (1) CA3067857A1 (https=)
WO (1) WO2018232452A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI818601B (zh) * 2021-10-29 2023-10-11 原創生醫股份有限公司 用於上呼吸道給藥之組成物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
WO2008137747A1 (en) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
AU2016228976B2 (en) * 2015-03-11 2018-11-08 University Of Cincinnati Compositions and methods for treating bacterial infection
EP3383415B1 (en) * 2015-12-01 2021-03-31 Cornell University Use of mitochondrial iron chelators for treatment of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
AU2023270302A1 (en) 2023-12-14
EP3641749A4 (en) 2021-03-17
AU2023270302B2 (en) 2025-10-23
AU2018286649B2 (en) 2023-11-09
US20200163920A1 (en) 2020-05-28
JP2025098035A (ja) 2025-07-01
JP2020524173A (ja) 2020-08-13
BR112019027257A2 (pt) 2020-07-14
JP2023071952A (ja) 2023-05-23
JP7729713B2 (ja) 2025-08-26
WO2018232452A1 (en) 2018-12-27
JP7848150B2 (ja) 2026-04-20
AU2018286649A1 (en) 2019-12-05
US11491126B2 (en) 2022-11-08
EP3641749A1 (en) 2020-04-29
US20230045633A1 (en) 2023-02-09
CN111050762A (zh) 2020-04-21

Similar Documents

Publication Publication Date Title
Wenzler et al. Inhaled antibiotics for gram-negative respiratory infections
Kim et al. Polyhexamethylene guanidine phosphate aerosol particles induce pulmonary inflammatory and fibrotic responses
Sermet-Gaudelus et al. Nebulized antibiotics in cystic fibrosis
AU2023285900B2 (en) Method For Reducing Lung Infection
US20120058198A1 (en) Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
JP4745340B2 (ja) 細菌性呼吸器感染症を治療するためのエーロゾル化されたホスホマイシン／アミノグリコシド組合せ
Stockmann et al. Clinical pharmacokinetics of inhaled antimicrobials
JP2025098035A (ja) 肺炎症を低減させる方法
Krishna et al. Liposomal drug delivery to the lungs: a post covid-19 scenario
Sheikh et al. Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?
TW201138785A (en) Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease
Toso et al. Inhaled antibiotics in cystic fibrosis: a review
US7012091B1 (en) Inhalable inhibitors of inflammation in the respiratory tract
Hasan et al. Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics
BR122025016291A2 (pt) Uso do agente quelante ácido etilenodiamino tetra-acético (edta) na fabricação de uma formulação inalável, formulação inalável e kit para tratar ou prevenir inflamação no pulmão
Narasimhan et al. New and investigational treatments in cystic fibrosis
US20170020838A1 (en) Treatment for respiratory disease
US7015244B1 (en) Inhalable chemical debridement for COPD
WO2021205074A1 (en) Inhalable formulation
Bensman Therapeutic Potential of Rhesus Theta (θ) Defensin-1 in Cystic Fibrosis Airway Infection and Inflammation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220215

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20240715

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20240909

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U107 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REFUND REQUEST RECEIVED

Effective date: 20240925

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250715

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260211